Resource Summary Report

Generated by ASWG on Aug 9, 2026

PerCP/Cyanine5.5 anti-human CD38

RRID:AB_2562183
Type: Antibody

Proper Citation

BioLegend Cat# 356614, RRID:AB_2562183

Antibody Information

URL: http://antibodyregistry.org/AB_2562183

Proper Citation: BioLegend Cat# 356614, RRID:AB_2562183

Target Antigen: CD38

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-human CD38

Description: This monoclonal targets CD38

Target Organism: human

Clone ID: Clone HB-7

Antibody ID: AB_2562183

Vendor: BioLegend

Catalog Number: 356614

Alternative Catalog Numbers: 356613

Record Creation Time: 20250820T023854+0000

Record Last Update: 20250820T140841+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-human CD38.

No alerts have been found for PerCP/Cyanine5.5 anti-human CD38.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at ASWG .

Gu H, et al. (2026) FAP??+ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(18), e06239.

Conti A, et al. (2025) Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9/AAV6-mediated gene editing in hematopoietic stem cells. Cell reports. Medicine, 6(6), 102157.

Hosking MP, et al. (2025) Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. Cell stem cell, 32(7), 1087.

Zhou C, et al. (2024) Nynrin preserves hematopoietic stem cell function by inhibiting the mitochondrial permeability transition pore opening. Cell stem cell, 31(9), 1359.

Della Volpe L, et al. (2024) A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells. Cell reports. Medicine, 5(11), 101823.

Ferrari S, et al. (2022) Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells. Cell stem cell, 29(10), 1428.

Omer-Javed A, et al. (2022) Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells. Cell, 185(13), 2248.

Zhou R, et al. (2020) Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity, 53(4), 864.

Petrillo C, et al. (2018) Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells. Cell stem cell, 23(6), 820.